Skip to main content

Table 1 CTX levels in different groups

From: Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments

  

CTX isoform

Subjects

 

αL CTX/Cr

βL CTX/Cr

αD CTX/Cr

Premenopausal patients

Mean ± standard deviation

3.65 ± 1.41

5.74 ± 3.46

1.75 ± 0.94

Postmenopausal patients

Mean ± standard deviation

8.39 ± 3.01

13. 6 ± 3.9

3.62 ± 1.08

 

P, U testa

< 0.001

< 0.001

< 0.001

 

T scorea

3.4

2.3

2.0

Normocalcemic breast cancer patients without bone metastases

Mean ± standard deviation

10.2 ± 6.23

12.7 ± 11.3

4.73 ± 4.14

 

P, U testb

Not significant

Not significant

Not significant

 

Z scoreb

0.60

-0.23

1.03

Normocalcemic breast cancer patients with bone metastases

Mean ± standard deviation

22.6 ± 24.8

24.6 ± 18.4

7.95 ± 9.11

 

P, U testc

< 0.01

< 0.01

< 0.05

 

Z scorec

2.00

1.01

0.76

Hypercalcemic breast cancer patients with bone metastases

Mean ± standard deviation

35.1 ± 27.8

38.0 ± 23.7

11.3 ± 10.2

 

P, U testc

< 0.01

< 0.01

< 0.05

 

Z scorec

3.41

2.24

1.59

  1. Concentrations are provided as μmol/mol. αD = D-aspartyl peptide; αL = L-aspartyl peptide; βL = L-isoaspartyl peptide; Cr, creatinine; CTX, crosslinked C-telopeptide of type I collagen. aVersus premenopausal patients. bVersus postmenopausal patients. cVersus normocalcemic breast cancer patients without bone metastases.